Iavi

Iavi company information, Employees & Contact Information

Explore related pages

Iavi email format Iavi management contacts

Related company profiles:

Translating scientific discoveries into affordable, globally accessible public health solutions. IAVI is a non-profit that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases.

Company Details

Employees
390
Founded
-
Address
125 Broad St,
Phone
212.847.1111
Email
in****@****avi.org
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Website
iavi.org
Keywords
AIDS vaccine, research and development, product development partnership, HIV/AIDS, vaccine development, global health, capacity strengthening, clinical trials, scientific research.
HQ
New York, NY
Competitors
Drugs for Neglected Diseases initiative (DNDi), International Vaccine Institute (IVI), Gates Foundation, The Global Fund, PATH, IQVIA, CEPI (Coalition for Epidemic Preparedness Innovations), Clinton Health Access Initiative, Inc., Sabin Vaccine Institute, Gavi, the Vaccine Alliance.
Looking for a particular Iavi employee's phone or email?

Iavi Questions

News

IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa - IAVI

IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa IAVI

Two HIV vaccine trials show proof of concept for pathway to broadly neutralizing antibodies - IAVI

Two HIV vaccine trials show proof of concept for pathway to broadly neutralizing antibodies IAVI

Phase 1 clinical trial of HIV vaccine starts in Africa to evaluate immune responses to highly networked HIV T-cell epitopes - IAVI

Phase 1 clinical trial of HIV vaccine starts in Africa to evaluate immune responses to highly networked HIV T-cell epitopes IAVI

IAVI and Biofabri/Zendal announce first vaccinations in the IMAGINE clinical trial, a large-scale safety and efficacy trial of the tuberculosis vaccine candidate MTBVAC - IAVI

IAVI and Biofabri/Zendal announce first vaccinations in the IMAGINE clinical trial, a large-scale safety and efficacy trial of the tuberculosis vaccine candidate MTBVAC IAVI

Picking up the pieces - IAVI

Picking up the pieces IAVI

First participants vaccinated with IAVI’s Ebola Sudan vaccine candidate in Uganda amid Ebola outbreak - IAVI

First participants vaccinated with IAVI’s Ebola Sudan vaccine candidate in Uganda amid Ebola outbreak IAVI

IAVI announces termination of the PEPFAR-funded ADVANCE program and staff reductions - IAVI

IAVI announces termination of the PEPFAR-funded ADVANCE program and staff reductions IAVI

New momentum for monoclonal antibodies manufacturing in Africa - IAVI

New momentum for monoclonal antibodies manufacturing in Africa IAVI

IAVI and IPD sign agreement formalizing collaboration to advance vaccine development, manufacturing, and access in Africa - IAVI

IAVI and IPD sign agreement formalizing collaboration to advance vaccine development, manufacturing, and access in Africa IAVI

Scientists reveal encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach - IAVI

Scientists reveal encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach IAVI

Careers - IAVI

Careers IAVI

IAVI announces first vaccinations at Liberia site in Phase 1 clinical trial of Lassa fever vaccine candidate - IAVI

IAVI announces first vaccinations at Liberia site in Phase 1 clinical trial of Lassa fever vaccine candidate IAVI

Participants in Nigeria vaccinated in first-ever Phase 2 Lassa fever vaccine clinical trial, sponsored by IAVI - IAVI

Participants in Nigeria vaccinated in first-ever Phase 2 Lassa fever vaccine clinical trial, sponsored by IAVI IAVI

HIV Vaccines - IAVI

HIV Vaccines IAVI

IAVI and Moderna launch first-in-Africa clinical trial of mRNA HIV vaccine development program - IAVI

IAVI and Moderna launch first-in-Africa clinical trial of mRNA HIV vaccine development program IAVI

IAVI and Moderna partner to tackle broad global health priorities using mRNA for vaccines and antibodies - IAVI

IAVI and Moderna partner to tackle broad global health priorities using mRNA for vaccines and antibodies IAVI

IAVI and Moderna launch trial of HIV vaccine antigens delivered through mRNA technology - IAVI

IAVI and Moderna launch trial of HIV vaccine antigens delivered through mRNA technology IAVI

Africa CDC and IAVI sign Memorandum of Understanding to enhance vaccine and antibody research capacity in Africa - IAVI

Africa CDC and IAVI sign Memorandum of Understanding to enhance vaccine and antibody research capacity in Africa IAVI

IAVI and partners kick-start CELEBRATE study to explore acceptability and feasibility of bnAbs for infant HIV prevention - IAVI

IAVI and partners kick-start CELEBRATE study to explore acceptability and feasibility of bnAbs for infant HIV prevention IAVI

Scientific Publications - IAVI

Scientific Publications IAVI

Discovery - IAVI

Discovery IAVI

IAVI and Zendal announce funding for efficacy trial of promising TB vaccine candidate in Africa - IAVI

IAVI and Zendal announce funding for efficacy trial of promising TB vaccine candidate in Africa IAVI

Zendal and IAVI announce expanded agreement to partner on development of TB vaccine candidate MTBVAC - IAVI

Zendal and IAVI announce expanded agreement to partner on development of TB vaccine candidate MTBVAC IAVI

Product Development - IAVI

Product Development IAVI

ReiThera Srl, the Ragon Institute and IAVI announce collaboration to advance highly networked T-cell HIV vaccine candidate towards Phase 1 clinical evaluation - IAVI

ReiThera Srl, the Ragon Institute and IAVI announce collaboration to advance highly networked T-cell HIV vaccine candidate towards Phase 1 clinical evaluation IAVI

IAVI statement on mRNA HIV vaccine candidate trials - IAVI

IAVI statement on mRNA HIV vaccine candidate trials IAVI

IAVI launches multisite study with adolescent girls and young women to evaluate vaccine and antibody candidates for HIV prevention in sub-Saharan Africa - IAVI

IAVI launches multisite study with adolescent girls and young women to evaluate vaccine and antibody candidates for HIV prevention in sub-Saharan Africa IAVI

IAVI to accelerate promising investigational Sudan ebolavirus vaccine development for potential outbreak research and response - IAVI

IAVI to accelerate promising investigational Sudan ebolavirus vaccine development for potential outbreak research and response IAVI

IAVI starts first-in-human Phase 1 clinical trial of single-dose Sudan virus vaccine candidate - IAVI

IAVI starts first-in-human Phase 1 clinical trial of single-dose Sudan virus vaccine candidate IAVI

Advocacy & Community Engagement - IAVI

Advocacy & Community Engagement IAVI

IAVI Sudan vaccine arrives in Entebbe in response to Ebola outbreak - IAVI

IAVI Sudan vaccine arrives in Entebbe in response to Ebola outbreak IAVI

IAVI announces renewed support from the Danish government for its HIV prevention program - IAVI

IAVI announces renewed support from the Danish government for its HIV prevention program IAVI

IAVI Vaccine Literacy Library: Module 1 - IAVI

IAVI Vaccine Literacy Library: Module 1 IAVI

IAVI and Scripps Research Join Efforts with NIH to Expedite Development of Globally Accessible and Affordable HIV Antibody Combination Products - IAVI

IAVI and Scripps Research Join Efforts with NIH to Expedite Development of Globally Accessible and Affordable HIV Antibody Combination Products IAVI

Don’t Stop Believin’: This year’s HIV vaccine research theme - IAVI

Don’t Stop Believin’: This year’s HIV vaccine research theme IAVI

First-ever Phase 2 Lassa vaccine clinical trial now fully active across West Africa - IAVI

First-ever Phase 2 Lassa vaccine clinical trial now fully active across West Africa IAVI

HIV Antibodies - IAVI

HIV Antibodies IAVI

Diversity, Equity, & Inclusion - IAVI

Diversity, Equity, & Inclusion IAVI

Merck and IAVI Discontinue Development of COVID-19 Vaccine Candidate V590 - IAVI

Merck and IAVI Discontinue Development of COVID-19 Vaccine Candidate V590 IAVI

Expanding access to monoclonal antibody-based products: A global call to action - IAVI

Expanding access to monoclonal antibody-based products: A global call to action IAVI

Terms of Use - IAVI

Terms of Use IAVI

Saluting Nelson Mandela, a Champion of AIDS Awareness - IAVI

Saluting Nelson Mandela, a Champion of AIDS Awareness IAVI

IAVI statement on PrEPVacc trial - IAVI

IAVI statement on PrEPVacc trial IAVI

What are monoclonal antibodies, and can they treat COVID-19? - IAVI

What are monoclonal antibodies, and can they treat COVID-19? IAVI

Tuberculosis - IAVI

Tuberculosis IAVI

Broadly neutralizing antibodies and their use in HIV research - IAVI

Broadly neutralizing antibodies and their use in HIV research IAVI

Novel HIV vaccine candidate stimulates immune response in T cells - IAVI

Novel HIV vaccine candidate stimulates immune response in T cells IAVI

First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research - IAVI

First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research IAVI

IAVI Acquires Aeras TB Vaccine Clinical Programs and Assets - IAVI

IAVI Acquires Aeras TB Vaccine Clinical Programs and Assets IAVI

CEPI partner IAVI announces first vaccinations at Liberia site in Phase I clinical trial of Lassa Fever vaccine candidate - CEPI

CEPI partner IAVI announces first vaccinations at Liberia site in Phase I clinical trial of Lassa Fever vaccine candidate CEPI

Companies like Iavi

International Vaccine Institute (IVI) logo - Similar company to Iavi

International Vaccin...

347
Clinton Health Access Initiative, Inc. logo - Similar company to Iavi

Clinton Health Acces...

2.17K
The Global Fund logo - Similar company to Iavi

The Global Fund

2.67K
Drugs for Neglected Diseases initiative (DNDi) logo - Similar company to Iavi

Drugs For Neglected ...

422
PATH logo - Similar company to Iavi

Path

3.44K
IQVIA logo - Similar company to Iavi

Iqvia

78.32K
Gates Foundation logo - Similar company to Iavi

Gates Foundation

4.07K
Sabin Vaccine Institute logo - Similar company to Iavi

Sabin Vaccine Institute

126
CEPI (Coalition for Epidemic Preparedness Innovations) logo - Similar company to Iavi

Cepi (Coalition For ...

509
Gavi, the Vaccine Alliance logo - Similar company to Iavi

Gavi, The Vaccine Al...

909

Top Iavi Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant